Showing 1651-1660 of 2165 results for "".
Understanding the Signs, Symptoms, and Latest Therapeutic Recommendations for NK
https://modernod.com/mod-issues/supplements-inserts/understanding-the-signs-symptoms-and-latest-therapeutic-recommendations-for-nk/38932/Norlase Launches First Pattern Scanning LIO
https://modernod.com/podcasts/eyewire-news-the-podcast/norlase-launches-first-pattern-scanning-lio/37069/The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchGlaukos Submits NDA for Epi-On CLX Candidate
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-submits-nda-for-epi-on-clx-candidate/37066/Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit mB+L Bolsters Glaucoma Offerings with Elios Acquisition
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-bolsters-glaucoma-offerings-with-elios-acquisition/37063/Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhase 3 Results for Novel Sedation Tablet
https://modernod.com/podcasts/eyewire-news-the-podcast/phase-3-results-for-novel-sedation-tablet/37062/New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoicesSpecial Report: OWL Celebrates 20th Anniversary
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-owl-celebrates-20th-anniversary/37060/Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary. Learn more about your ad choices. Visit megaphone.fm/adchoices85. Case Reflection: One Dot Heme
https://modernod.com/podcasts/four-eyes/85-case-reflection-one-dot-heme/37035/In this episode of our New Grad Case Reflection series, Dr. Kar shares an interesting case of one (small but mighty) dot hemorrhage causing chaos for the doctor and the patient. How far would you go to investigate one minor finding in the retina? Join Dr. Kar as she reflects on the case that was shLumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
https://modernod.com/podcasts/eyewire-news-the-podcast/lumithera-ceo-discusses-fda-authorization-for-veleda-for-dry-amd/37059/The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.Ophthalmic Executives Provide Company Updates (Part 2 of 2)
https://modernod.com/podcasts/eyewire-news-the-podcast/ophthalmic-executives-provide-company-updates-part-2-of-2/37058/Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV.Ophthalmic Executives Provide Company Updates (Part 1 of 2)
https://modernod.com/podcasts/eyewire-news-the-podcast/ophthalmic-executives-provide-company-updates-part-1-of-2/37057/We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development.